Conditions: Cholangiocarcinoma
Keywords: Biliary Duct Cancer Cancer of the Gallbladder Adenocarcinoma of the Gall Bladder Adenocarcinoma of the Biliary Ducts Cholangiocarcinoma Extrahepatic cholangiocarcinoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 50
Healthy volunteers: no

Brief summary:
To assess the proposed therapy for patients with advanced gallbladder or biliary cancers.

Detailed description:
The primary objective of this study is to assess progression free survival with proposed therapy for patients with locally advanced or metastatic adenocarcinoma of the gallbladder or biliary ducts.

Arms:
arm 1: Estimate the toxicity of the regimen, and estimate the quality of life (QOL).

Interventions: intervention 1: Gemcitabine, Capecitabine and Bevacizumab
Intervention descriptions: intervention 1: Bevacizumab 15 mg/ kg every 3 weeks, starting day 1; Capecitabine 650 mg/m2 bid x 14 days starting day 1, Gemcitabine 1000 mg/m2 days 1 and 8, cycles to be repeated every 21 days.

Protocol document: